Clinical Trials

Blood Tests for Alzheimer’s Are Finally Real. Here Is What They Do — and Don’t — Change.

Four FDA-cleared blood assays for Alzheimer’s pathology now exist, with the newest cleared for use in primary care. The accuracy data is genuinely good for symptomatic patients. Almost everything the internet claims about the numbers is still wrong.

Revuelt Health · October 20, 2026 · 10 min read

Ashwagandha: What the Trials Actually Show — and What the Regulators Found

The adaptogen is one of the most-studied botanicals on the supplement shelf, with more than $165 million in annual U.S. sales. The stress data is better than most herbs can claim, the safety story is worse than most buyers assume, and one European country has made it illegal to sell.

Revuelt Health · October 20, 2026 · 10 min read

Low-Dose Naltrexone: A Small Dose, A Large Set of Claims

A fifty-year-old opioid blocker, prescribed at a tenth of its approved dose for fibromyalgia, long COVID, ME/CFS and MS. The mechanistic story is elegant, the trial record is messier — and 2026 delivered an uncomfortable correction to the field’s most-cited positive number.

Revuelt Health · October 20, 2026 · 10 min read

Long COVID in 2026: What Actually Helped, and What Still Hasn't

Six years and well over a billion dollars into the federal government's largest long COVID research effort, one trial has produced a durable benefit — and it isn't a drug. A look at what the 2026 data actually supports, and what is still a hypothesis wearing a press release.

Revuelt Health · September 15, 2026 · 10 min read

40 Hz: The Frequency Therapy That Is About to Be Tested Properly

A light flickering and a tone pulsing forty times a second, an hour a day, at home. The mouse work launched a field, one large replication attempt found none of it, and a 670-person sham-controlled trial is due to report before the year is out.

Revuelt Health · September 15, 2026 · 9 min read

Fecal Transplants Beyond C. diff: What Is Approved, What Is Promising, and What Got Harder to Get

Transferring a healthy person's gut microbes into a sick person's colon is an approved, guideline-backed treatment — for exactly one condition. This year the field finally produced randomized data outside that condition, a regulator said no to the most advanced product in Europe, and a manufactured alternative matched donor stool in a head-to-head trial. None of it points the same direction.

Revuelt Health · September 15, 2026 · 13 min read

Acupuncture for Chronic Pain: What the Guidelines Actually Say

A majority of clinical practice guideline recommendations support it. Almost none of them support it strongly. Both facts come from the same review, and the gap between them is the whole story.

Revuelt Health · August 9, 2026 · 9 min read

MDMA-Assisted Therapy After the Rejection: Where the Work Stands

A Phase 3 programme produced some of the largest effect sizes in modern psychiatry. The regulator was not persuaded — and what it objected to was not, in the main, the effect size.

Revuelt Health · August 9, 2026 · 10 min read

The New Wave of Psilocybin Trials for Treatment-Resistant Depression

Phase II results were striking enough to sustain a decade of interest. The larger trials now underway will decide whether the effect holds outside a small, carefully selected room.

Revuelt Health · July 21, 2026 · 9 min read

TMS Therapy, and the Five-Day Protocol That Changed the Conversation

Magnetic stimulation of the prefrontal cortex has been FDA-cleared for depression since 2008. Stanford's accelerated version compressed six weeks into five days.

Revuelt Health · July 18, 2026 · 9 min read

Updated August 5, 2026

Photobiomodulation: What Red and Near-Infrared Light Can and Cannot Do

Light therapy has moved from fringe device to serious research question. The evidence is strongest exactly where the marketing is quietest.

Revuelt Health · June 2, 2026 · 6 min read

Updated July 31, 2026